Salix climbs after FDA OKs Xifaxan
NEW YORK |
NEW YORK (Reuters) - Salix Pharmaceuticals Ltd (SLXP.O) shares jumped 6.8 percent to $35.80 in premarket trade on Thursday after the U.S. Food and Drug Administration late Wednesday approved the company's Xifaxan antibiotic as a treatment for reducing the risk of a liver disorder in adults.
(Reporting by Chuck Mikolajczak)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters